Prescription Description
| Prescription ID | TCMF1052 |
| Pinyin Name | Shu Jin Tong Luo Ke Li |
| Chinese Name | 舒筋通络颗粒 |
| English Name | Shu Jin Tong Luo Granules |
| Function Description | 颈椎病 |
| Indications | None |
| Disease ICD-11 Category | |
| Human Tissues Associated with Indication | SkeletaMuscle |
| Reference | Chinese pharmacopoeia (2015) |
| Reference Book/link | ISBN 978-7-5067-7337-9 |
Prescription Components
| Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
|---|---|---|---|---|
| TCMH700 | Drynaria fortunei | 骨碎补 | TCMH700 | GBVM3977-11 |
| TCMH305 | Cnidium officinale | 川芎 | TCMH305 | ITSAP4207-14 |
| TCMH1588 | Achyranthes bidentata | 牛膝 | TCMH1588 | ITSAJ4612-14 |
| TCMH2090 | Gastrodia elata | 天麻 | TCMH2090 | |
| TCMH981 | Astragalus membranaceus | 黄芪 | TCMH981 | ITSAK2981-14 |
| TCMH2166 | Clematis chinensis | 威灵仙 | TCMH2166 | |
| TCMH456 | Rhizoma dioscoreae nipponicae | 地龙 | TCMH456 | |
| TCMH677 | Pueraria lobata | 葛根 | TCMH677 | ITSAJ4206-14 |
| TCMH1753 | Boswellia carterii | 乳香 | TCMH1753 |
Targeted Human Proteins by the Ingredients of Prescription
| Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
|---|---|---|---|---|
| TCMT101 | PTPN1 | Protein-tyrosine phosphatase 1B | Hydrolase | P18031 |
| TCMT107 | GRIK2 | Glutamate receptor ionotropic kainate 2 | Ion channel | Q13002 |
| TCMT109 | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | Ion channel | P42262 |
| TCMT110 | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | Ion channel | P48058 |
| TCMT111 | GRIK5 | Glutamate receptor ionotropic kainate 5 | Ion channel | Q16478 |
| TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
| TCMT13 | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | Lyase | P27695 |
| TCMT130 | ALOX5 | Arachidonate 5-lipoxygenase | Oxidoreductase | P09917 |
| TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
| TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
| TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
| TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
| TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
| TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
| TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
| TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
| TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
| TCMT174 | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | Oxidoreductase | P28845 |
| TCMT187 | AR | Androgen Receptor | Nuclear receptor | P10275 |
| TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
| TCMT2 | MAPT | Microtubule-associated protein tau | Unclassified | P10636 |
| TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
| TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
| TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
| TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
| TCMT236 | ESR2 | Estrogen receptor beta | Nuclear receptor | Q92731 |
| TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
| TCMT280 | AKR1B10 | Aldo-keto reductase family 1 member B10 | Oxidoreductase | O60218 |
| TCMT295 | MMP1 | Matrix metalloproteinase-1 | Hydrolase | P03956 |
| TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
| TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
| TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
| TCMT306 | MMP2 | Matrix metalloproteinase-2 | Hydrolase | P08253 |
| TCMT318 | HKDC1 | Putative hexokinase HKDC1 | Transferase | Q2TB90 |
| TCMT321 | MMP9 | Matrix metalloproteinase 9 | Hydrolase | P14780 |
| TCMT332 | AOC3 | Amine oxidase, copper containing | Oxidoreductase | Q16853 |
| TCMT344 | AOX1 | Aldehyde oxidase | Oxidoreductase | Q06278 |
| TCMT44 | GLO1 | Glyoxalase I | Lyase | Q04760 |
| TCMT558 | TOP2A | DNA topoisomerase II alpha | Isomerase | P11388 |
| TCMT563 | CDC25B | Dual specificity phosphatase Cdc25B | Hydrolase | P30305 |
| TCMT591 | ESRRA | Estrogen-related receptor alpha | Nuclear receptor | P11474 |
| TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
| TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
| TCMT599 | UBE2N | Ubiquitin-conjugating enzyme E2 N | Transferase | P61088 |
| TCMT613 | NR3C1 | Glucocorticoid receptor | Nuclear receptor | P04150 |
| TCMT614 | EGLN1 | Egl nine homolog 1 | Oxidoreductase | Q9GZT9 |
| TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
| TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
| TCMT653 | GRM1 | Metabotropic glutamate receptor 1 | GPCR | Q13255 |
| TCMT654 | GRM5 | Metabotropic glutamate receptor 5 | GPCR | P41594 |
| TCMT655 | GRM2 | Metabotropic glutamate receptor 2 | GPCR | Q14416 |
| TCMT656 | GRM3 | Metabotropic glutamate receptor 3 | GPCR | Q14832 |
| TCMT657 | GRM4 | Metabotropic glutamate receptor 4 | GPCR | Q14833 |
| TCMT660 | GRM8 | Metabotropic glutamate receptor 8 | GPCR | O00222 |
| TCMT664 | SLC1A1 | Excitatory amino acid transporter 3 | Transporter | P43005 |
| TCMT678 | XIAP | Inhibitor of apoptosis protein 3 | Transferase | P98170 |
| TCMT679 | MPEG1 | Macrophage-expressed gene 1 protein | Unclassified | Q2M385 |
| TCMT680 | KAT2B | Histone acetyltransferase PCAF | Transferase | Q92831 |
| TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
| TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
| TCMT737 | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Unclassified | Q9HC16 |
| TCMT740 | PIK3CG | PI3-kinase p110-gamma subunit | Transferase | P48736 |
| TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
| TCMT783 | NR3C2 | Mineralocorticoid receptor | Nuclear receptor | P08235 |
| TCMT8 | KDM4E | Lysine-specific demethylase 4D-like | Oxidoreductase | B2RXH2 |
| TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
| TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
| TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
| TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
| TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
| TCMT904 | PGR | Progesterone receptor | Nuclear receptor | P06401 |
| TCMT910 | ESRRB | Estrogen-related receptor beta | Nuclear receptor | O95718 |
| TCMT974 | GPER1 | G-protein coupled estrogen receptor 1 | GPCR | Q99527 |
| TCMT99 | SHBG | Testis-specific androgen-binding protein | Unclassified | P04278 |
Targeted Pathogenic Microbes by the Ingredients of Prescription
| Target ID | Target Name |
|---|---|
| TCMT1175 | Human immunodeficiency virus |
| TCMT1178 | Actinomyces viscosus |
| TCMT1189 | Pseudomonas fluorescens |
| TCMT1209 | Staphylococcus haemolyticus |
| TCMT1210 | Streptococcus sobrinus |
| TCMT1211 | Fusobacterium nucleatum |
| TCMT1212 | Verticillium dahliae |
| TCMT1218 | Staphylococcus aureus |
| TCMT1222 | Plasmodium falciparum D6 |
| TCMT1223 | Staphylococcus epidermidis |
| TCMT1226 | Klebsiella pneumoniae |
| TCMT1227 | Streptococcus |
| TCMT1229 | Enterococcus faecalis |
| TCMT1231 | Human herpesvirus 1 strain KOS |
| TCMT1232 | Pseudomonas aeruginosa |
| TCMT1245 | Phytophthora cactorum |
| TCMT1246 | Escherichia coli |
| TCMT1247 | Human herpesvirus 1 |
| TCMT1248 | Hepatitis C virus |
| TCMT1251 | Candida albicans |
| TCMT1253 | Penicillium chrysogenum |
| TCMT1255 | Human immunodeficiency virus 1 |
| TCMT1284 | Penicillium expansum |
| TCMT1286 | Bacillus cereus |
| TCMT1294 | Human parainfluenza virus 3 |
| TCMT1321 | Staphylococcus hominis |
| TCMT1343 | Staphylococcus simulans |
| TCMT1344 | Staphylococcus sciuri |
| TCMT1346 | Helicobacter pylori |
| TCMT1349 | Helicobacter pylori SS1 |
| TCMT1361 | Neisseria meningitidis |
| TCMT1370 | Prevotella melaninogenica |
| TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
| TCMT1390 | Human herpesvirus 2 strain G |
| TCMT1408 | Colletotrichum gloeosporioides |
| TCMT1412 | Salmonella typhimurium |
| TCMT1438 | Plasmodium falciparum |
| TCMT1442 | Leishmania donovani |
| TCMT1443 | Leishmania amazonensis |
| TCMT1447 | Respiratory syncytial virus |
| TCMT1448 | Enterobacter aerogenes |
| TCMT1449 | Influenza A virus |
| TCMT1450 | Plasmodium falciparum 3D7 |
| TCMT1454 | Bacillus subtilis |
| TCMT1455 | Mycobacterium tuberculosis H37Rv |
| TCMT1458 | Filobasidiella neoformans |
| TCMT1462 | Streptococcus mutans |
| TCMT1463 | Mycobacterium tuberculosis |
| TCMT1464 | Hepatitis B virus |
| TCMT1465 | Entamoeba histolytica |
Gene Ontology Associated to Targeted Human Proteins
| GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|---|
| [BP] GO:0043401 | steroid hormone mediated signaling pathway | AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, NR3C1, NR3C2, PGR, PPARA | 8.30495 |
| [BP] GO:0009755 | hormone-mediated signaling pathway | AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, NR3C1, NR3C2, PGR, PPARA | 7.26413 |
| [BP] GO:0007215 | None | GRIA2, GRIA4, GRIK5, GRM1, GRM3, GRM5, GRM8 | 7.26413 |
| [BP] GO:0006367 | transcription initiation from RNA polymerase II promoter | AR, ESR1, ESR2, ESRRA, ESRRB, NR3C1, NR3C2, PGR, PPARA | 6.06443 |
| [BP] GO:0030522 | intracellular receptor signaling pathway | AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, NR3C1, PGR, PPARA | 5.75369 |
| [BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA7 | 5.57512 |
| [BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, APEX1, AR, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, GPER1, GRIK5, GRM5, MMP2, MMP9, NR3C1, PPARA | 5.34755 |
| [BP] GO:0006352 | DNA-templated transcription, initiation | AR, ESR1, ESR2, ESRRA, ESRRB, NR3C1, NR3C2, PGR, PPARA | 5.34755 |
| [BP] GO:0007196 | None | GRM1, GRM3, GRM5, GRM8 | 5.20522 |
| [BP] GO:0050804 | modulation of chemical synaptic transmission | ACHE, ADORA1, CA2, CA7, GPER1, GRIK5, GRM1, GRM3, GRM5, GRM8 | 5.14763 |
| [BP] GO:0099177 | regulation of trans-synaptic signaling | ACHE, ADORA1, CA2, CA7, GPER1, GRIK5, GRM1, GRM3, GRM5, GRM8 | 5.14763 |
| [BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALOX5, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FABP3, FABP4, FUT7, HSD11B1, HSD17B1, PPARA | 5.00899 |
| [BP] GO:0009725 | response to hormone | AKR1B1, ALPL, APEX1, AR, CA2, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, GPER1, NR3C1, PPARA | 4.8601 |
| [BP] GO:0008202 | steroid metabolic process | AKR1B1, AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, HSD11B1, HSD17B1 | 4.82192 |
| [BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD17B1 | 4.61725 |
| [BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, APEX1, AR, CA2, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, GPER1, GRM5, MMP2, NR3C1, PPARA | 4.61725 |
| [BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA7 | 4.55003 |
| [BP] GO:0007216 | None | GRM1, GRM3, GRM5, GRM8 | 4.52345 |
| [BP] GO:0030518 | intracellular steroid hormone receptor signaling pathway | AR, ESR1, ESR2, GPER1, NR3C1, PGR | 4.39436 |
| [BP] GO:0019748 | secondary metabolic process | AKR1B1, AKR1B10, CYP1A1, CYP1A2, CYP1B1 | 3.85837 |
| [BP] GO:0044281 | small molecule metabolic process | AKR1B1, AKR1B10, ALOX5, AOX1, CA1, CA12, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FUT7, GLO1, PPARA, XDH | 3.76206 |
| [BP] GO:0014070 | response to organic cyclic compound | ALPL, APEX1, AR, CA2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, GPER1, NR3C1 | 3.64661 |
| [BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1 | 3.64609 |
| [BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, APEX1, AR, CA12, CA2, CA7, CYP19A1, CYP1A1, CYP1B1, ESR1, FABP3, FABP4, GPER1, GRIA2, GRIA4, GRIK5, GRM1, GRM5, HSD11B1, HSD17B1, PPARA, SLC1A1, XDH | 3.63923 |
| [BP] GO:0051966 | regulation of synaptic transmission, glutamatergic | ADORA1, GRM1, GRM3, GRM5, GRM8 | 3.60244 |
| [BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, APEX1, AR, CA2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, GPER1, GRIK5, GRM5, MMP2, NR3C1, PPARA | 3.54878 |
| [BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, GPER1, HSD11B1, HSD17B1 | 3.36842 |
| [BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA7, FABP3, PPARA, SLC1A1 | 3.14194 |
| [BP] GO:0007193 | None | ADORA1, GRM1, GRM3, GRM5, GRM8 | 3.10758 |
| [BP] GO:0048522 | positive regulation of cellular process | ACHE, ADORA1, AKR1B1, APEX1, AR, CA2, CA7, CDC25B, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP3, GPER1, GRIK5, GRM1, GRM5, MMP1, MMP2, MMP9, NR3C1, PGR, PPARA, PTPN1, TOP2A, XDH | 3.09916 |
| [BP] GO:0060078 | None | ADORA1, GRIA2, GRIA4, GRIK5, GRM5 | 3.0943 |
| [BP] GO:2001225 | regulation of chloride transport | CA2, CA7, GRM5 | 3.08393 |
| [BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.08393 |
| [BP] GO:0048518 | positive regulation of biological process | ACHE, ADORA1, AKR1B1, APEX1, AR, CA2, CA7, CDC25B, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP3, FABP4, GPER1, GRIK5, GRM1, GRM5, MMP1, MMP2, MMP9, NR3C1, PGR, PPARA, PTPN1, SLC1A1, TOP2A, XDH | 3.05789 |
| [BP] GO:0060736 | prostate gland growth | AR, CYP19A1, ESR1 | 2.96048 |
| [BP] GO:0033993 | response to lipid | ALPL, AR, CA2, CSNK2A1, CYP1A1, CYP1A2, ESR1, ESRRA, FABP3, GPER1, NR3C1 | 2.94298 |
| [BP] GO:0042221 | response to chemical | AKR1B1, ALPL, APEX1, AR, CA2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, GPER1, GRIK5, GRM5, MMP2, MMP9, NR3C1, PPARA | 2.86179 |
| [BP] GO:0007188 | None | ADORA1, GPER1, GRM1, GRM3, GRM5, GRM8 | 2.85539 |
| [BP] GO:0055114 | oxidation-reduction process | AKR1B1, AKR1B10, ALOX5, AOX1, APEX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD17B1, XDH | 2.85133 |
| [BP] GO:0071407 | cellular response to organic cyclic compound | ALPL, APEX1, AR, CYP1A1, CYP1B1, ESR1, GPER1, NR3C1 | 2.81605 |
| [BP] GO:1901701 | cellular response to oxygen-containing compound | AKR1B1, APEX1, AR, CYP1B1, ESR1, GPER1, GRIK5, GRM5, MMP2, MMP9, NR3C1 | 2.78997 |
| [BP] GO:0007267 | None | ADORA1, AR, ESR2, GRIA2, GRIK5, GRM1, GRM3, GRM5, PGR, SLC1A1 | 2.68815 |
| [BP] GO:0070887 | cellular response to chemical stimulus | AKR1B1, ALPL, APEX1, AR, CYP1A1, CYP1A2, CYP1B1, ESR1, FABP4, GPER1, GRIK5, GRM5, MMP2, MMP9, NR3C1 | 2.67241 |
| [BP] GO:0009115 | None | AOX1, XDH | 2.66864 |
| [BP] GO:0016042 | lipid catabolic process | ADORA1, AKR1B10, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4 | 2.60908 |
| [BP] GO:0007187 | None | ADORA1, GPER1, GRM1, GRM3, GRM5, GRM8 | 2.52698 |
| [BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA7, FABP3, PPARA, SLC1A1 | 2.37881 |
| [BP] GO:0023052 | None | ADORA1, AR, ESR2, GRIA2, GRIK5, GRM1, GRM3, GRM5, PGR, SLC1A1 | 2.35554 |
| [BP] GO:0071310 | cellular response to organic substance | AKR1B1, ALPL, APEX1, AR, CYP1A1, CYP1B1, ESR1, FABP4, GPER1, GRIK5, GRM5, MMP2, NR3C1 | 2.33474 |
| [BP] GO:0009056 | catabolic process | ACHE, ADORA1, AKR1B10, AOX1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, MMP1, MMP2, MMP9, XDH | 2.29949 |
| [BP] GO:0099566 | None | GRM1, GRM5 | 2.29035 |
| [BP] GO:0060748 | None | AR, PGR | 2.29035 |
| [BP] GO:0046110 | None | AOX1, XDH | 2.29035 |
| [BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.29035 |
| [BP] GO:0042127 | regulation of cell proliferation | ADORA1, ADORA3, AKR1B1, AR, CDC25B, CSNK2A1, CYP1B1, ESR1, ESRRA, FABP3, GPER1, MMP2, MMP9, PGR, XDH | 2.29006 |
| [BP] GO:0010941 | regulation of cell death | ADORA1, AKR1B1, APEX1, AR, CSNK2A1, CYP1B1, ESR1, GLO1, GPER1, GRIK5, MMP9, PPARA, PTPN1, TOP2A, XDH | 2.27895 |
| [BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD17B1 | 2.27822 |
| [BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 2.25443 |
| [BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.13616 |
| [BP] GO:0010035 | response to inorganic substance | AKR1B1, APEX1, CA2, CYP1A1, CYP1A2, CYP1B1, FABP4, MMP9 | 2.12113 |
| [BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1 | 2.0963 |
| [BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.0963 |
| [BP] GO:0042180 | None | AKR1B1, AKR1B10, CYP19A1, GLO1 | 2.0963 |
| [BP] GO:0060079 | None | ADORA1, GRIA2, GRIA4, GRIK5 | 2.0963 |
| [BP] GO:0042981 | regulation of apoptotic process | ADORA1, AKR1B1, APEX1, AR, CSNK2A1, CYP1B1, ESR1, GLO1, GPER1, GRIK5, MMP9, PTPN1, TOP2A, XDH | 2.09345 |
| [BP] GO:0051716 | cellular response to stimulus | AKR1B1, ALPL, APEX1, AR, CA2, CYP1A1, CYP1A2, CYP1B1, ESR1, FABP4, GPER1, GRIK5, GRM1, GRM5, MMP2, MMP9, NR3C1, PTPN1, TOP2A | 2.09345 |
| [BP] GO:0048878 | chemical homeostasis | AKR1B1, CA12, CA2, CA7, ESR1, FABP3, FABP4, GPER1, GRIK5, GRM1, GRM5 | 2.07386 |
| [BP] GO:0043067 | regulation of programmed cell death | ADORA1, AKR1B1, APEX1, AR, CSNK2A1, CYP1B1, ESR1, GLO1, GPER1, GRIK5, MMP9, PTPN1, TOP2A, XDH | 2.07386 |
| [BP] GO:0006145 | None | AOX1, XDH | 2.07386 |
| [BP] GO:0032847 | regulation of cellular pH reduction | CA2, CA7 | 2.07386 |
| [BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.07386 |
| [BP] GO:0019220 | regulation of phosphate metabolic process | ADORA1, AR, CDC25B, ESRRB, FABP3, FABP4, GPER1, GRM1, GRM3, GRM5, GRM8, MMP9, PPARA, PTPN1, XDH | 2.06257 |
| [BP] GO:0007165 | signal transduction | ADORA1, ADORA3, AKR1B1, AR, CA1, CA2, CSNK2A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, GPER1, GRIA2, GRIA4, GRIK5, GRM1, GRM3, GRM5, GRM8, MMP2, MMP9, NR3C1, NR3C2, PGR, PPARA, PTPN1 | 2.05271 |
| [BP] GO:0035235 | None | GRIA2, GRIA4, GRIK5 | 2.04448 |
| [BP] GO:0051174 | regulation of phosphorus metabolic process | ADORA1, AR, CDC25B, ESRRB, FABP3, FABP4, GPER1, GRM1, GRM3, GRM5, GRM8, MMP9, PPARA, PTPN1, XDH | 2.03342 |
| [BP] GO:0044255 | cellular lipid metabolic process | ACHE, AKR1B10, ALOX5, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, PPARA | 2.02623 |
| [CC] GO:0042734 | None | GPER1, GRIK5, GRM1, GRM3, GRM5, GRM8 | 4.86821 |
| [CC] GO:0097060 | None | GPER1, GRIA2, GRIA4, GRIK5, GRM1, GRM3, GRM5, GRM8 | 3.36521 |
| [CC] GO:0098590 | plasma membrane region | ADORA1, CA2, CA4, GPER1, GRIA2, GRIA4, GRIK5, GRM1, GRM3, GRM5, GRM8, SLC1A1 | 2.52698 |
| [CC] GO:0014069 | None | ADORA1, GPER1, GRIK5, GRM1, GRM3, GRM5 | 2.36651 |
| [CC] GO:0099572 | None | ADORA1, GPER1, GRIK5, GRM1, GRM3, GRM5 | 2.36651 |
| [CC] GO:0044456 | None | ACHE, ADORA1, GPER1, GRIA2, GRIA4, GRIK5, GRM1, GRM3, GRM5, GRM8 | 2.36651 |
| [MF] GO:0046914 | transition metal ion binding | ALOX5, AOX1, AR, CA1, CA12, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, GLO1, MMP1, MMP2, MMP9, NR3C1, NR3C2, PGR, PPARA, PTPN1, XDH | 14.0866 |
| [MF] GO:0005496 | steroid binding | AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, HSD17B1, NR3C1, NR3C2, PGR, SHBG | 11.3926 |
| [MF] GO:0003707 | steroid hormone receptor activity | AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, NR3C1, NR3C2, PGR, PPARA | 11.3926 |
| [MF] GO:0008270 | zinc ion binding | AR, CA1, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, GLO1, MMP1, MMP2, MMP9, NR3C1, NR3C2, PGR, PPARA, PTPN1 | 9.00555 |
| [MF] GO:0008066 | None | GRIA2, GRIA4, GRIK5, GRM1, GRM3, GRM5, GRM8 | 8.62352 |
| [MF] GO:0098531 | transcription factor activity, direct ligand regulated sequence-specific DNA binding | AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, PGR, PPARA | 8.62352 |
| [MF] GO:0004879 | nuclear receptor activity | AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, PGR, PPARA | 8.62352 |
| [MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA7 | 8.3708 |
| [MF] GO:0016835 | carbon-oxygen lyase activity | APEX1, CA1, CA12, CA14, CA2, CA4, CA7 | 5.68279 |
| [MF] GO:0043169 | cation binding | ACHE, ALOX5, ALPL, AOX1, APEX1, AR, CA1, CA12, CA14, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, GLO1, MMP1, MMP2, MMP9, NR3C1, NR3C2, PGR, PPARA, PTPN1, SLC1A1, TOP2A, XDH | 5.68279 |
| [MF] GO:0038023 | signaling receptor activity | ADORA1, ADORA3, AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, GRIA2, GRIA4, GRIK5, GRM1, GRM3, GRM5, GRM8, NR3C1, NR3C2, PGR, PPARA | 5.65273 |
| [MF] GO:0008289 | lipid binding | AR, ESR1, ESR2, ESRRA, ESRRB, FABP3, FABP4, GPER1, HSD17B1, NR3C1, NR3C2, PGR, PPARA, SHBG | 5.51846 |
| [MF] GO:0046872 | metal ion binding | ALOX5, ALPL, AOX1, APEX1, AR, CA1, CA12, CA14, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, GLO1, MMP1, MMP2, MMP9, NR3C1, NR3C2, PGR, PPARA, PTPN1, SLC1A1, TOP2A, XDH | 5.34755 |
| [MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA7 | 5.13909 |
| [MF] GO:0004872 | receptor activity | ADORA1, ADORA3, AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, GRIA2, GRIA4, GRIK5, GRM1, GRM3, GRM5, GRM8, NR3C1, NR3C2, PGR, PPARA | 5.00899 |
| [MF] GO:0060089 | molecular transducer activity | ADORA1, ADORA3, AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, GRIA2, GRIA4, GRIK5, GRM1, GRM3, GRM5, GRM8, NR3C1, NR3C2, PGR, PPARA | 4.83118 |
| [MF] GO:0016829 | lyase activity | APEX1, CA1, CA12, CA14, CA2, CA4, CA7, GLO1 | 4.61725 |
| [MF] GO:0004871 | signal transducer activity | ADORA1, ADORA3, AR, ESR1, ESR2, ESRRA, ESRRB, GPER1, GRIA2, GRIA4, GRIK5, GRM1, GRM3, GRM5, GRM8, NR3C1, NR3C2, PGR, PPARA | 4.45856 |
| [MF] GO:0043167 | ion binding | ACHE, ALOX5, ALPL, AOX1, APEX1, AR, CA1, CA12, CA14, CA2, CA4, CA7, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP3, FABP4, GLO1, HSD17B1, MMP1, MMP2, MMP9, NR3C1, NR3C2, PGR, PPARA, PTPN1, SLC1A1, TOP2A, XDH | 4.21248 |
| [MF] GO:0042562 | hormone binding | ACHE, AR, GPER1, HSD17B1, NR3C1, SHBG | 4.19183 |
| [MF] GO:0030284 | estrogen receptor activity | ESR1, ESR2, GPER1 | 3.98635 |
| [MF] GO:0005506 | iron ion binding | ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, XDH | 3.86605 |
| [MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.68154 |
| [MF] GO:0016491 | oxidoreductase activity | AKR1B1, AKR1B10, ALOX5, AOX1, APEX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD17B1, XDH | 3.64609 |
| [MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.51952 |
| [MF] GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | AKR1B1, AKR1B10, AOX1, HSD11B1, HSD17B1, XDH | 3.12971 |
| [MF] GO:0016903 | None | AKR1B1, AKR1B10, AOX1, XDH | 2.70638 |
| [MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 2.67907 |
| [MF] GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | ESR1, ESR2 | 2.66864 |
| [MF] GO:0009055 | electron transfer activity | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.49754 |
| [MF] GO:0030594 | None | GRIA2, GRIA4, GRIK5, GRM1, GRM5 | 2.48351 |
| [MF] GO:0004970 | None | GRIA2, GRIA4, GRIK5 | 2.33857 |
| [MF] GO:0005234 | None | GRIA2, GRIA4, GRIK5 | 2.33857 |
| [MF] GO:0099583 | None | GRM1, GRM5 | 2.29035 |
| [MF] GO:0034056 | estrogen response element binding | ESR1, ESR2 | 2.07386 |
| [MF] GO:0004971 | None | GRIA2, GRIA4 | 2.07386 |
| [MF] GO:0005497 | None | AR, SHBG | 2.07386 |
KEGG Pathways Associated to Targeted Human Proteins
| KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|
| Glutamatergic synapse_Homo sapiens_hsa04724 | GRM3, GRIA2, GRM5, GRIK5, GRM8, SLC1A1, GRM1, GRIA4 | 7.5116 |
| Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA2, CA4, CA7, CA14 | 9.5091 |
| Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | GRM3, GRIA2, GRM5, ADORA3, GRIK5, GRM8, ADORA1, NR3C1, GRM1, GRIA4 | 7.0752 |
| Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD11B1, HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 6.6325 |
| Ovarian steroidogenesis_Homo sapiens_hsa04913 | ALOX5, HSD17B1, CYP1A1, CYP1B1, CYP19A1 | 5.4022 |
| Estrogen signaling pathway_Homo sapiens_hsa04915 | MMP2, GPER1, MMP9, ESR1, GRM1, ESR2 | 5.4022 |
| Tryptophan metabolism_Homo sapiens_hsa00380 | CYP1A2, CYP1A1, AOX1, CYP1B1 | 4.2764 |
| Metabolic pathways_Homo sapiens_hsa01100 | HSD11B1, FUT7, AKR1B10, ALOX5, HSD17B1, CYP1A2, CYP1A1, AOX1, ALPL, AKR1B1, CYP19A1, XDH | 3.2059 |
| Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.3377 |
| PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4, MMP1, PPARA | 3.3832 |
| Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | GRIA2, GRM5, GRM1, GRIA4 | 2.9469 |
| Chemical carcinogenesis_Homo sapiens_hsa05204 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.2097 |
| Phospholipase D signaling pathway_Homo sapiens_hsa04072 | GRM3, GRM5, GRM8, GRM1 | 2.4216 |
| Bladder cancer_Homo sapiens_hsa05219 | MMP1, MMP2, MMP9 | 2.9087 |
| Long-term potentiation_Homo sapiens_hsa04720 | GRIA2, GRM5, GRM1 | 2.3807 |
| Retinol metabolism_Homo sapiens_hsa00830 | CYP1A2, CYP1A1, AOX1 | 2.3807 |
| cAMP signaling pathway_Homo sapiens_hsa04024 | GRIA2, ADORA1, PPARA, GRIA4 | 2.0038 |
| Proteoglycans in cancer_Homo sapiens_hsa05205 | MMP2, MMP9, ESR1 | 1.3017 |
| Pathways in cancer_Homo sapiens_hsa05200 | AR, MMP1, MMP2, MMP9 | 1.2165 |
| Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4, ADORA1 | 1.4162 |
| Amphetamine addiction_Homo sapiens_hsa05031 | GRIA2, GRIA4 | 1.3164 |
| Long-term depression_Homo sapiens_hsa04730 | GRIA2, GRM1 | 1.3921 |
| Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B10, AKR1B1 | 1.3921 |
| Prolactin signaling pathway_Homo sapiens_hsa04917 | ESR1, ESR2 | 1.3017 |
| Cocaine addiction_Homo sapiens_hsa05030 | GRM3, GRIA2 | 1.5105 |
| Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP1A2, AOX1 | 1.3074 |
| Nicotine addiction_Homo sapiens_hsa05033 | GRIA2, GRIA4 | 1.6637 |
| Adherens junction_Homo sapiens_hsa04520 | PTPN1, CSNK2A1 | 1.3017 |
| Circadian entrainment_Homo sapiens_hsa04713 | GRIA2, GRIA4 | 1.1407 |
| Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | PGR, CDC25B | 1.1277 |
| Galactose metabolism_Homo sapiens_hsa00052 | AKR1B10, AKR1B1 | 1.8492 |
| Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B10, AKR1B1 | 1.7342 |
| Gap junction_Homo sapiens_hsa04540 | GRM5, GRM1 | 1.1903 |
| Insulin resistance_Homo sapiens_hsa04931 | PTPN1, PPARA | 1.0544 |
| MicroRNAs in cancer_Homo sapiens_hsa05206 | CYP1B1, MMP9, CDC25B | 0.9935 |
| Oocyte meiosis_Homo sapiens_hsa04114 | AR, PGR | 1.0026 |
| Sphingolipid signaling pathway_Homo sapiens_hsa04071 | ADORA3, ADORA1 | 1.0115 |
| Leukocyte transendothelial migration_Homo sapiens_hsa04670 | MMP2, MMP9 | 1.014 |
| Dopaminergic synapse_Homo sapiens_hsa04728 | GRIA2, GRIA4 | 0.9855 |
| Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B10, AKR1B1 | 1.815 |
| Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.0338 |
| cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | ADORA3, ADORA1 | 0.8248 |
| Calcium signaling pathway_Homo sapiens_hsa04020 | GRM5, GRM1 | 0.7967 |
| Prostate cancer_Homo sapiens_hsa05215 | AR | 0.5293 |
| Taste transduction_Homo sapiens_hsa04742 | GRM1 | 0.5293 |
| AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | MMP2 | 0.5187 |
| GnRH signaling pathway_Homo sapiens_hsa04912 | MMP2 | 0.5293 |
| Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.5293 |
| TNF signaling pathway_Homo sapiens_hsa04668 | MMP9 | 0.4963 |
| Cholinergic synapse_Homo sapiens_hsa04725 | ACHE | 0.4963 |
| Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.5588 |
| Morphine addiction_Homo sapiens_hsa05032 | ADORA1 | 0.5293 |
| Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.5187 |
| Rheumatoid arthritis_Homo sapiens_hsa05323 | MMP1 | 0.5293 |
| Measles_Homo sapiens_hsa05162 | CSNK2A1 | 0.4605 |
| FoxO signaling pathway_Homo sapiens_hsa04068 | GRM1 | 0.4605 |
| MAPK signaling pathway_Homo sapiens_hsa04010 | CDC25B | 0.3064 |
| Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | ESR1 | 0.4876 |
| Hepatitis C_Homo sapiens_hsa05160 | PPARA | 0.4605 |
| Peroxisome_Homo sapiens_hsa04146 | XDH | 0.5293 |
| Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1 | 0.3759 |
| Serotonergic synapse_Homo sapiens_hsa04726 | ALOX5 | 0.4963 |
| Insulin signaling pathway_Homo sapiens_hsa04910 | PTPN1 | 0.4605 |
| Hepatitis B_Homo sapiens_hsa05161 | MMP9 | 0.4553 |
| Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA | 0.5682 |
| Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.5265 |
| Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.4042 |
| Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | ESRRB | 0.4605 |
| NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1 | 0.527 |
| Toxoplasmosis_Homo sapiens_hsa05145 | ALOX5 | 0.4876 |
| Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PPARA | 0.4482 |
| Cell cycle_Homo sapiens_hsa04110 | CDC25B | 0.4746 |
| Jak-STAT signaling pathway_Homo sapiens_hsa04630 | AOX1 | 0.4369 |
| Huntington's disease_Homo sapiens_hsa05016 | GRM5 | 0.3866 |
| Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.4605 |
| Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.4605 |
| Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | MMP9 | 0.4011 |
| Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.3963 |
| Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.5265 |
| Protein digestion and absorption_Homo sapiens_hsa04974 | SLC1A1 | 0.5293 |
| Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.5682 |
| Renin secretion_Homo sapiens_hsa04924 | ADORA1 | 0.5953 |
| Arachidonic acid metabolism_Homo sapiens_hsa00590 | ALOX5 | 0.6008 |
| Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | GRIA2 | 0.6724 |
| Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | ESR1 | 0.6906 |
| Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | AOX1 | 0.6895 |
| Drug metabolism - other enzymes_Homo sapiens_hsa00983 | XDH | 0.6916 |
| Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | NR3C2 | 0.7438 |
| Pyruvate metabolism_Homo sapiens_hsa00620 | GLO1 | 0.7414 |
| Tyrosine metabolism_Homo sapiens_hsa00350 | AOX1 | 0.7804 |
| Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.8055 |
| Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.8248 |
| Base excision repair_Homo sapiens_hsa03410 | APEX1 | 0.7967 |
| Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | AOX1 | 0.8248 |
| Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.8333 |
| Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.8271 |
| Caffeine metabolism_Homo sapiens_hsa00232 | CYP1A2, XDH | 3.2097 |
| Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 1.0334 |
| Vitamin B6 metabolism_Homo sapiens_hsa00750 | AOX1 | 1.3017 |
Target Exprsssion in Healthy Human Tissues (protein & mRNA level)
Protein expression data was from the "Human Proteome Map" datasetmRNA expression data was from the "GTEx" dataset
Average Target Expression (Fold Change) in Multiple Disease Conditions
Fold Change with Corresponding Normal SamplesClick each cell within the heatmap to access gene expression of individual patient samples